Content area

Abstract

In the past decade, evidence for a fluid clearance pathway in the central nervous system known as the glymphatic system has grown. According to the glymphatic system concept, cerebrospinal fluid flows directionally through the brain and non-selectively clears the interstitium of metabolic waste. Importantly, the glymphatic system may be modulated by particular drugs such as anaesthetics, as well as by non-pharmacological factors such as sleep, and its dysfunction has been implicated in central nervous system disorders such as Alzheimer disease. Although the glymphatic system is best described in rodents, reports using multiple neuroimaging modalities indicate that a similar transport system exists in the human brain. Here, we overview the evidence for the glymphatic system and its role in disease and discuss opportunities to harness the glymphatic system therapeutically; for example, by improving the effectiveness of intrathecally delivered drugs.

Evidence for a fluid clearance pathway in the central nervous system known as the glymphatic system has grown in the past decade. Nedergaard and colleagues overview the evidence for the glymphatic system and its role in disease, and discuss opportunities to harness the glymphatic system therapeutically; for example, by improving the effectiveness of intrathecally delivered drugs.

Details

Title
The glymphatic system: implications for drugs for central nervous system diseases
Author
Lohela, Terhi J. 1   VIAFID ORCID Logo  ; Lilius, Tuomas O. 2   VIAFID ORCID Logo  ; Nedergaard, Maiken 3 

 University of Copenhagen, Center for Translational Neuromedicine, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X); University of Helsinki, Individualized Drug Therapy Research Program, Faculty of Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Helsinki University Hospital and University of Helsinki, Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666); Helsinki University Hospital and University of Helsinki, Department of Emergency Medicine and Services, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666) 
 University of Copenhagen, Center for Translational Neuromedicine, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X); University of Helsinki, Individualized Drug Therapy Research Program, Faculty of Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Helsinki University Hospital and University of Helsinki, Department of Emergency Medicine and Services, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666); University of Helsinki, Department of Pharmacology, Faculty of Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071) 
 University of Copenhagen, Center for Translational Neuromedicine, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X); University of Rochester Medical Center, Center for Translational Neuromedicine, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166) 
Pages
763-779
Publication year
2022
Publication date
Oct 2022
Publisher
Nature Publishing Group
ISSN
14741776
e-ISSN
14741784
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2719627912
Copyright
© Springer Nature Limited 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.